Kenvue Inc. (KVUE) has a MoatMap StockRank of 75/100 based on Quality (55/100), Value (43/100), and Momentum (61/100) factor scores. The current signal is BUY. Kenvue is a slow-growing consumer health giant with strong brands but lacks the high-velocity growth or macro inflection tailwinds required for our concentrated book.
Kenvue Inc. is a pure-play consumer health company, spun off from Johnson & Johnson, that boasts an unparalleled portfolio of iconic, market-leading brands across Self Care, Skin Health & Beauty, and Essential Health segments, including Tylenol, Band-Aid, and Neutrogena. The company's formidable competitive moat stems from deep consumer trust, global brand recognition, extensive R&D capabilities, and a vast distribution network inherited from its former parent. This collection of household names ensures resilient demand in the defensive consumer health sector.
| Price | $17.59 |
| Market Cap | $33.9B |
| P/E (TTM) | 20.10 |
| P/E (Forward) | 13.65 |
| Price/Book | 3.06 |
| Return on Equity | 15.7% |
| Return on Invested Capital | 11.5% |
| Debt/Equity | 82.97 |
| Gross Margin | 58.6% |
| Operating Margin | 21.6% |
| Revenue Growth | 4.5% |
| Dividend Yield | 4.9% |
| Free Cash Flow | $1.9B |
Kenvue Inc. operates in the Household & Personal Products industry, part of the Consumer Defensive sector (United States).